Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

15.02.2024 - Received 459 new patient start forms (PSFs) for FILSPARI (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval ...

Related Keywords

Liechtenstein ,Iceland ,Japan ,Norway ,Deric Dube ,Drug Administration ,European Union ,Devices Agency ,Program Updates ,Committee For Medicinal Products Human Use ,Nasdaq ,Renalys Pharma Inc ,Travere Therapeutics Inc ,Exchange Commission ,Continuing Operations ,Quarter Ended December ,New Drug Application ,Medicinal Products ,Human Use ,Conditional Marketing Authorization ,Renalys Pharma ,Medical Devices Agency ,Kidney Disease Improving Global Outcomes ,Clinical Practice Guideline ,Focal Segmental Glomerulosclerosis ,Travere Therapeutics ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Practice Guideline ,Glomerular Diseases ,Months Ended December ,Travere Thereapeutics Chart ,Ravere Thereapeutics Kurs ,Ravere Thereapeutics Aktie ,